Henneman John III Buys Shares of Aprea Therapeutics

Henneman John III recently made an insider purchase of Aprea Therapeutics, Inc. (NasdaqCM: APRE), acquiring 12,555 shares on June 16, 2026. The transaction comes as the stock trades near $0.73 per share.

Insider Buying and Selling at Aprea Therapeutics, Inc.

Henneman John III's recent purchase is part of a series of insider transactions at Aprea Therapeutics. On the same day, several other insiders, including Bernd Seizinger and Rifat Pamukcu, also bought shares. These transactions were not planned under Rule 10b5-1 plans.

Other Institutional Activity in Aprea Therapeutics

Several institutional investors have also been active in Aprea Therapeutics. AIGH Capital Management LLC increased its holdings by 645,000 shares, ending with 1,015,541 shares valued at approximately $774,757. Geode Capital Management, LLC boosted its position by 78,181 shares to a total of 119,131 shares worth about $90,890. Meanwhile, Sphera Funds Management Ltd. and Nantahala Capital Management, LLC held steady with their existing positions.

Aprea Therapeutics, Inc. Stock Down 7.0%

Shares of Aprea Therapeutics, Inc. (NasdaqCM: APRE) are trading near $0.73. The company has a market capitalization of around $9.66 million. It carries a forward P/E ratio that is not meaningful as the company is not currently profitable. The stock's 52-week range is between $0.55 and $2.22, with a 50-day moving average of $0.85 and a 200-day moving average of $1.02.

Analysts Set New Price Targets

Analysts are optimistic about Aprea Therapeutics. On May 14, 2026, Wedbush maintained its 'buy' rating with a price target of $6.00. Oppenheimer initiated coverage on May 7, 2026, with a 'buy' rating and a $5.00 target. The consensus among analysts is a 'strong buy', with a mean target price of $4.30 based on four opinions.

About Aprea Therapeutics

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Doylestown, Pennsylvania. It focuses on developing cancer therapies that target DNA damage response pathways. Its leading product candidates include APR-1051, in Phase 1 trials for advanced solid tumors, and ATRN-119, in Phase 1/2a trials for solid tumors. The company is led by CEO Dr. Oren Gilad, Ph.D., and employs eight people.

Bottom Line

Insider purchases at Aprea Therapeutics suggest confidence in the company's prospects. Investors often track such activity for potential insights into a company's future. While the company's stock price remains low, analyst ratings indicate optimism with a strong buy consensus. However, it's important to remember that insider transactions are just one piece of the investment puzzle.